NASDAQ:SMTI Sanara MedTech (SMTI) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free SMTI Stock Alerts $30.51 -1.19 (-3.75%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$30.00▼$32.3550-Day Range$29.28▼$37.7252-Week Range$26.06▼$46.40Volume17,482 shsAverage Volume15,151 shsMarket Capitalization$263.30 millionP/E RatioN/ADividend YieldN/APrice Target$44.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Sanara MedTech alerts: Email Address Sanara MedTech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside44.2% Upside$44.00 Price TargetShort InterestBearish4.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.92 out of 5 starsMedical Sector808th out of 914 stocksSurgical Appliances & Supplies Industry16th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingSanara MedTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSanara MedTech has only been the subject of 1 research reports in the past 90 days.Read more about Sanara MedTech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted4.20% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Sanara MedTech has recently increased by 3.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSanara MedTech does not currently pay a dividend.Dividend GrowthSanara MedTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMTI. Previous Next 1.0 News and Social Media Coverage News SentimentSanara MedTech has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Sanara MedTech this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sanara MedTech insiders have not sold or bought any company stock.Percentage Held by Insiders54.10% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.10% of the stock of Sanara MedTech is held by institutions.Read more about Sanara MedTech's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanara MedTech is -51.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanara MedTech is -51.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSanara MedTech has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sanara MedTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Sanara MedTech Stock (NASDAQ:SMTI)Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Read More SMTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMTI Stock News HeadlinesMay 18 at 5:26 AM | americanbankingnews.comFY2024 EPS Estimates for Sanara MedTech Inc. (NASDAQ:SMTI) Cut by AnalystMay 17 at 6:06 AM | americanbankingnews.comSanara MedTech (NASDAQ:SMTI) Stock Rating Reaffirmed by Cantor FitzgeraldMay 15, 2024 | insidermonkey.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid ...May 14, 2024 | investorplace.comSMTI Stock Earnings: Sanara MedTech Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | finance.yahoo.comSanara MedTech Inc. Reports First Quarter 2024 Results: Revenue Surges, Losses WidenMay 13, 2024 | globenewswire.comSanara MedTech Inc. Announces First Quarter 2024 ResultsMay 12, 2024 | finance.yahoo.comInsiders own 30% of Sanara MedTech Inc. (NASDAQ:SMTI) shares but individual investors control 32% of the companyMay 11, 2024 | americanbankingnews.comSanara MedTech (SMTI) Scheduled to Post Earnings on MondayApril 29, 2024 | globenewswire.comSanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call DatesApril 18, 2024 | globenewswire.comSanara MedTech Inc. Announces $55 Million Debt FacilityApril 11, 2024 | investing.comSanara Medtech Inc (SMTI)April 5, 2024 | markets.businessinsider.comSanara MedTech Names Jake Waldrop COO, Effective April 15; Stock Up In Pre-marketApril 5, 2024 | globenewswire.comSanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy OfficerMarch 29, 2024 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | seekingalpha.comSanara MedTech Inc. (SMTI) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | investorplace.comSMTI Stock Earnings: Sanara MedTech Beats EPS, Beats Revenue for Q4 2023March 25, 2024 | finance.yahoo.comSanara MedTech Inc (SMTI) Reports Strong Sales Growth and Reduced Net Loss for Full Year 2023March 25, 2024 | globenewswire.comSanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 ResultsMarch 22, 2024 | benzinga.comSanara MedTech's Earnings: A PreviewMarch 13, 2024 | finance.yahoo.comInvestors in Sanara MedTech (NASDAQ:SMTI) have seen fantastic returns of 541% over the past five yearsMarch 13, 2024 | globenewswire.comSanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call DatesMarch 6, 2024 | benzinga.comCGI Cellerate RX, LLC's Net WorthFebruary 23, 2024 | benzinga.comSanara MedTech Stock (NASDAQ:SMTI), Analyst Ratings, Price Targets, PredictionsFebruary 22, 2024 | globenewswire.comSanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023See More Headlines Receive SMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/19/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:SMTI CUSIPN/A CIK714256 Webwww.wndm.com Phone(817) 529-2300FaxN/AEmployees107Year FoundedN/APrice Target and Rating Average Stock Price Target$44.00 High Stock Price Target$44.00 Low Stock Price Target$44.00 Potential Upside/Downside+44.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-7.19% Pretax Margin-7.39% Return on Equity-11.33% Return on Assets-7.02% Debt Debt-to-Equity Ratio0.20 Current Ratio1.35 Quick Ratio1.04 Sales & Book Value Annual Sales$64.99 million Price / Sales4.05 Cash FlowN/A Price / Cash FlowN/A Book Value$4.99 per share Price / Book6.11Miscellaneous Outstanding Shares8,630,000Free Float3,959,000Market Cap$263.30 million OptionableNot Optionable Beta1.67 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ronald T. Nixon (Age 68)Executive Chairman Mr. Zachary B. Fleming (Age 49)Chief Executive Officer Comp: $593.64kMr. Michael D. McNeil (Age 59)CFO & Corporate Secretary Comp: $438.68kDr. Christopher A. Morrison FACHM (Age 54)FAPWCA, FCCWS, M.D., President of Telehealth Services Comp: $156kMr. Bill FitzgeraldChief Compliance OfficerMs. Tricia MattesonVice President of MarketingMr. Tyler PalmerChief Corporate Development & Strategy OfficerDr. Rebecca Erin Mcmahon (Age 39)President of Research & Development Mr. Seth YonPresident of CommercialMore ExecutivesKey CompetitorsInogenNASDAQ:INGNCollPlant BiotechnologiesNASDAQ:CLGNJin Medical InternationalNASDAQ:ZJYLAvanos MedicalNYSE:AVNSCodexisNASDAQ:CDXSView All CompetitorsInstitutional OwnershipPrice T Rowe Associates Inc. MDBought 322 shares on 5/15/2024Ownership: 0.067%Vanguard Group Inc.Bought 4,348 shares on 5/10/2024Ownership: 1.675%Janney Montgomery Scott LLCSold 1,017 shares on 5/1/2024Ownership: 0.166%Quadrature Capital LtdSold 8,775 shares on 3/25/2024Ownership: 0.080%View All Institutional Transactions SMTI Stock Analysis - Frequently Asked Questions Should I buy or sell Sanara MedTech stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares. View SMTI analyst ratings or view top-rated stocks. What is Sanara MedTech's stock price target for 2024? 1 Wall Street analysts have issued 1 year target prices for Sanara MedTech's stock. Their SMTI share price targets range from $44.00 to $44.00. On average, they predict the company's stock price to reach $44.00 in the next year. This suggests a possible upside of 44.2% from the stock's current price. View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts. How have SMTI shares performed in 2024? Sanara MedTech's stock was trading at $41.10 at the beginning of the year. Since then, SMTI stock has decreased by 25.8% and is now trading at $30.51. View the best growth stocks for 2024 here. When is Sanara MedTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SMTI earnings forecast. How were Sanara MedTech's earnings last quarter? Sanara MedTech Inc. (NASDAQ:SMTI) posted its earnings results on Monday, March, 25th. The company reported ($0.03) earnings per share for the quarter. The firm earned $17.69 million during the quarter. Sanara MedTech had a negative net margin of 7.19% and a negative trailing twelve-month return on equity of 11.33%. What guidance has Sanara MedTech issued on next quarter's earnings? Sanara MedTech issued an update on its fourth quarter 2023 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.7 million-$17.7 million, compared to the consensus revenue estimate of $16.5 million. What other stocks do shareholders of Sanara MedTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), AC Immune (ACIU) and Applied Genetic Technologies (AGTC). Who are Sanara MedTech's major shareholders? Sanara MedTech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.67%), Janney Montgomery Scott LLC (0.17%) and Price T Rowe Associates Inc. MD (0.07%). Insiders that own company stock include Shawn M Bowman and Zachary B Fleming. View institutional ownership trends. How do I buy shares of Sanara MedTech? Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SMTI) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.